Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
There are limited data directly comparing humoral and T cell responses to the ChAdOx1 nCoV-19 and BNT162b2 vaccines. We compared Ab and T cell responses after first doses of ChAdOx1 nCoV-19 vs. BNT162b2 vaccines. We enrolled healthcare workers who received ChAdOx1 nCoV-19 or BNT162b2 vaccine in Seoul, Korea. Anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S1 protein-specific IgG Abs (S1-IgG), neutralizing Abs (NT Abs), and SARS-CoV-2-specific T cell response were evaluated before vaccination and at 1-wk intervals for 3 wks after vaccination. A total of 76 persons, comprising 40 injected with the ChAdOx1 vaccine and 36 injected with the BNT162b2 vaccine, participated in this study. At 3 wks after vaccination, the mean levels (±SD) of S1-IgG and NT Abs in the BNT162b2 participants were significantly higher than in the ChAdOx1 participants (S1-IgG, 14.03±7.20 vs. 6.28±8.87, p<0.0001; NT Ab, 183.1±155.6 vs. 116.6±116.2, p=0.035), respectively. However, the mean values of the T cell responses in the 2 groups were comparable after 2 wks. The humoral immune response after the 1st dose of BNT162b2 developed faster and was stronger than after the 1st dose of ChAdOx1. However, the T cell responses to BNT162b2 and ChAdOx1 were similar.
Abstract
There are limited data directly comparing humoral and T cell responses to the ChAdOx1 nCoV-19 and BNT162b2 vaccines. We compared Ab and T cell responses after first doses of ChAdOx1 nCoV-19 vs. BNT162b2 vaccines. We enrolled healthcare workers who received ChAdOx1 nCoV-19 or BNT162b2 vaccine in Seoul, Korea. Anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S1 protein-specific IgG Abs (S1-IgG), neutralizing Abs (NT Abs), and SARS-CoV-2-specific T cell response were evaluated before vaccination and at 1-wk intervals for 3 wks after vaccination. A total of 76 persons, comprising 40 injected with the ChAdOx1 vaccine and 36 injected with the BNT162b2 vaccine, participated in this study. At 3 wks after vaccination, the mean levels (±SD) of S1-IgG and NT Abs in the BNT162b2 participants were significantly higher than in the ChAdOx1 participants (S1-IgG, 14.03±7.20 vs. 6.28±8.87, p<0.0001; NT Ab, 183.1±155.6 vs. 116.6±116.2, p=0.035), respectively. However, the mean values of the T cell responses in the 2 groups were comparable after 2 wks. The humoral immune response after the 1st dose of BNT162b2 developed faster and was stronger than after the 1st dose of ChAdOx1. However, the T cell responses to BNT162b2 and ChAdOx1 were similar.
참고문헌 (23)
- Folegatti PM, "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 : a preliminary report of a phase 1", 2, single-blind, randomised controlled trial, 2020, pp.396, 467~478
- Pardi N, "Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes", J Control Release, 217, pp.345~351 (2015)
- Walsh EE, "Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates", N Engl J Med, 383, pp.2439~2450 (2020)
- Kalimuddin S, "Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset", Med(N Y), 2, pp.682.e4~688.e4 (2021)
- Müller L, "Age-dependent immune response to the Biontech", Pfizer BNT162b2 COVID-19 vaccination, 2021, ciab381~
- Krammer F, "Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine", N Engl J Med, 384, pp.1372~1374 (2021)
- van Doremalen N, "ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2pneumonia in rhesus macaques", Nature, 586, pp.578~582 (2020)
- McDonald I, "Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2", NPJ Vaccines, 6, pp.74~ (2021)
- Giurgea LT, "Navigating the quagmire: comparison and interpretation of COVID-19 vaccine phase 1", 2 clinical trials, 2020, pp.8, 746~
- Rogliani P, "SARS-CoV-2 neutralizing antibodies: a network metaanalysis across vaccines", Vaccines(Basel), 9, pp.227~ (2021)
- Kim JY, "SARSCoV-2-specific antibody and T cell response kinetics according to symptom severity", Am J Trop Med Hyg, pp.tpmd201594~ (2021)
- Classen DC, "Detection of antibody to murine cytomegalovirus by enzymelinked immunosorbent and indirect immunofluorescence assays", J Clin Microbiol, 25, pp.600~604 (1987)
- Lardeux F, "Calculation of the ELISA's cut-off based on the change-point analysis method for detection of Trypanosoma cruzi infection in Bolivian dogs in the absence of controls", Mem Inst Oswaldo Cruz, 111, pp.501~504 (2016)
- Ramasamy MN, "Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults(COV002) : a single-blind, randomised, controlled, phase 2", 3 trial, 2021, pp.396, 1979~1993
- Hasanpourghadi M, "COVID-19 vaccines based on adenovirus vectors", Trends Biochem Sci, 46, pp.429~430 (2021)
- Tomko RP, "HCAR and MCAR : the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses", Proc Natl Acad Sci U S A, 94, pp.3352~3356 (1997)
- Bergelson JM, "Finberg RW The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses", J Virol, 72, pp.415~419 (1998)
- Gilleron J, "Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape", Nat Biotechnol, 31, pp.638~646 (2013)
- Maruggi G, "mRNA as a transformative technology for vaccine development to control infectious diseases", Mol Ther, 27, pp.757~772 (2019)
- Ulmer JB, "Recent innovations in mRNA vaccines", Curr Opin Immunol, 41, pp.18~22 (2016)
- Vogel AB, "Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses", Mol Ther, 26, pp.446~455 (2018)
- Mateus J, "Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans", Science, 370, pp.89~94 (2020)
- Schmidt KG, "SARS-CoV-2-seronegative subjects target CTL epitopes in the SARS-CoV-2nucleoprotein cross-reactive to common cold coronaviruses", Front Immunol, 12, pp.627568~ (2021)